Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Necitumumab in advanced nonsquamous NSCLC
NCT00982111Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2009
- Primary completion
- Nov 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of necitumumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall Survival up to 31.6 Months. Started Nov 2009; status: completed.
02
Drugs
necitumumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT00982111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00982111.